Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel

BACKGROUND: Men with metastatic castrate-resistant prostate cancer (mCRPC) may not receive docetaxel in everyday clinical practice due to comorbidities. Here we explore the impact of comorbidity on outcome in men with mCRPC treated with docetaxel in a population-based outcome study. METHODS: Men wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zist, Andrej, Amir, Eitan, Ocana, Alberto F., Seruga, Bostjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722932/
https://www.ncbi.nlm.nih.gov/pubmed/26834528
http://dx.doi.org/10.1515/raon-2015-0038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722932/
https://www.ncbi.nlm.nih.gov/pubmed/26834528
http://dx.doi.org/10.1515/raon-2015-0038

Ejemplares similares